Sionna Therapeutics’ second-generation molecules, combined with standard CFTR modulators, fully restored the production and function of the CFTR…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
A high degree of genetic diversity was found among strains of Pseudomonas aeruginosa bacteria initially infecting the lungs of…
All the cystic fibrosis (CF) patients participating in the Phase 2 portion of a clinical trial have been dosed…
Journaling — writing thoughts and feelings to understand them more clearly — improved the mental health of adolescents with…
More than half of the infections caused by the Burkholderia cepacia complex (BCC), a bacteria known to cause serious complications…
Oral red ginseng extract eased the signs of cystic fibrosis (CF) in the lungs of rats, a study reports.
Telemedicine programs for managing cystic fibrosis (CF) were at least as effective as standard in-clinic care, according to a…
LasB, an enzyme that promotes Pseudomonas aeruginosa infections in the lungs of people with cystic fibrosis (CF), is…
A newly identified therapeutic target showed a potential to enhance the effectiveness of antibiotics against resistant Mycobacterium abscessus (Mabs) lung…
The U.S. Food and Drug Administration (FDA) will allow children with cystic fibrosis (CF) as young as age 2…